Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13579558 | 0.81 | ALDH1A1 (0.45) | CYP1A2TSHRHSD17B10CYP2C19 | |
| SCHEMBL13579593 | 0.81 | ALDH1A1 (0.45) | CYP1A2TSHRHSD17B10CYP2C19 | |
| SCHEMBL19738160 | 0.79 | ALDH1A1 (0.33) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL20383516 | 0.78 | KCNH2 (0.37) | TSHRMAPK1HSD17B10 | |
| SCHEMBL3306761 | 0.78 | CYP3A4 (0.34) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL21682147 | 0.78 | CYP3A4 (0.34) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1101682 | 0.78 | KCNH2 (0.37) | TSHRMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL21682149 | 0.78 | CYP3A4 (0.34) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL19738157 | 0.77 | MEN1 (0.36) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL19738166 | 0.73 | MMP2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | CYP3A4 4303/4885CYP1A2 2317/4885CYP2D6 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.